Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis

Hearing loss and nephrotoxicity are associated with prolonged treatment duration and higher dosage of amikacin and kanamycin. In our tuberculosis center, we used therapeutic drug monitoring (TDM) targeting preset pharmacokinetic/pharmacodynamic (PK/PD) surrogate endpoints in an attempt to maintain e...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: van Altena, R., Dijkstra, J. A., van der Meer, M. E., Borjas Howard, J. F., Kosterink, J. G. W., van Soolingen, D., van der Werf, T. S., Alffenaar, J. W. C.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2017
Matèries:
Clinical Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5328543/
https://ncbi.nlm.nih.gov/pubmed/28069654
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01400-16
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars